May 27, 2020 8:45 am EDT Volition Announces Cameron Reynolds, President and Chief Executive Officer Invited as Presenter at Maxim's COVID-19 Virtual Conference
May 22, 2020 4:01 pm EDT VolitionRx Announces Closing of $13.8 Million Public Offering of Common Stock
May 20, 2020 8:45 am EDT VolitionRx Announces Pricing of Underwritten Public Offering of Common Stock
May 13, 2020 5:00 pm EDT VolitionRx To Present First Data on Nu.Q™ Capture Performance and Nu.Q™ Assay Performance in Lung Cancer and Blood Cancer at the 2020 ASCO Annual Meeting
May 7, 2020 4:10 pm EDT VolitionRx Limited Announces First Quarter 2020 Financial Results and Business Update
May 5, 2020 8:30 am EDT VolitionRx Limited Schedules First Quarter 2020 Earnings Conference Call and Business Update
Apr 23, 2020 8:30 am EDT Volition Files Patent for Nu.Q(TM) COVID-19 Triage Test and Commences Proof of Concept Studies
